Although melanoma-specific survival did not differ significantly among patients with NRAS, BRAF, or wild-type tumors overall, the presence of NRAS or BRAF mutations in higher-risk tumors (stage T2b or above) was associated with notably increased mortality risk, an effect not seen in lower-risk tumors (stage T2a or below) [20]. Here, NRAS is linked to melanoma.